Table 1.
Demographic, clinical features, and BDNF serum levels in different study groups.
| Diagnosis | CTRL | AD | FTD | LBD | VAD | PD |
|---|---|---|---|---|---|---|
| Sample size | 169 | 266 | 28 | 40 | 91 | 30 |
| Demographic variables | ||||||
| Gender (% F) | 49% | 67% | 54% | 68% | 67% | 30% |
| differences versus CTRL P = | <0.001 | 0.688 | 0.052 | 0.006 | 0.073 | |
| Age | 48.0 ± 15.7 | 80.1 ± 7.1 | 71.7 ± 9.9 | 79.2 ± 5.6 | 81.9 ± 7.5 | 67.6 ± 8.4 |
| differences versus CTRL P = | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| Clinical variables | ||||||
| MMSE score | >27 | 13.6 ± 8.0 | 16.1 ± 6.6 | 15.9 ± 7.4 | 14.8 ± 8.0 | 25.4 ± 2.0 |
| HY score | 3.58 ± 0.5 | |||||
| Pharmacological treatment | ||||||
| Neuroleptics (−/+)* | 118/148 | 14/14 | 14/26 | 44/47 | 26/44 | |
| Benzodiazepines (−/+) | 167/99 | 17/11 | 28/12 | 58/33 | 30/0 | |
| Antidepressants (−/+) | 142/124 | 12/16 | 20/20 | 27/64 | 17/13 | |
| Mood stabilizers antiepileptics (−/+) | 237/29 | 20/8 | 37/3 | 74/17 | 30/0 | |
| Cholinesterase inhibitors (−/+) | 193/73 | 27/1 | 21/19 | 87/4 | 30/0 | |
| L-DOPA (−/+) | 266/0 | 28/0 | 40/0 | 91/0 | 0/30 | |
| Serum BDNF | ||||||
| ng/mL (mean ± SD) | 39.89 ± 9.48 | 33.16 ± 12.4 | 31.19 ± 9.68 | 31.71 ± 11.6 | 33.06 ± 12.4 | 46.13 ± 15.3 |
*(−/+): not treated/treated.